Clinical Trial Update: Nab-paclitaxel Plus PD-1 Inhibitor Versus Nab-paclitaxel As Second-line Treatment in Advanced Gastric Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing nab-paclitaxel plus a PD-1 inhibitor versus nab-paclitaxel alone as second-line therapy in advanced gastric and gastroesophageal cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Cancer

Drugs mentioned

• Abraxane (paclitaxel albumin-bound)
• PD-1 inhibitor

Snippet

Sponsor: Huazhong University of Science and Technology | Conditions: Gastric Cancer, GastroEsophageal Cancer | Phase 2 | Status: TERMINATED